Verastem, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Verastem, Inc. (VSTM) reported Cash and Cash Equivalents, Period Increase (Decrease) of $49.83 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-13
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $30.91M.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $23.69M.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$596.00K, a 102.44% decline year-over-year.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$4.17M.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $49.83M, a 566.23% increase from fiscal 2016.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $7.48M.
- Verastem, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$9.03M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $30.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $54.59M derived: sum of 2 quarters · filed 2018-03-13 | $54.00M derived: sum of 3 quarters · filed 2018-03-13 | $49.83M 10-K · filed 2018-03-13 |
| 2017-09-30 | $23.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $23.09M derived: sum of 2 quarters · filed 2017-11-07 | $18.92M 10-Q · filed 2017-11-07 | $14.00M derived: sum of 4 quarters · filed 2018-03-13 |
| 2017-06-30 | -$596.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$4.77M 10-Q · filed 2017-08-08 | -$9.69M derived: sum of 3 quarters · filed 2018-03-13 | -$11.98M derived: sum of 4 quarters · filed 2018-03-13 |
| 2017-03-31 | -$4.17M 10-Q · filed 2017-05-10 | -$9.10M derived: sum of 2 quarters · filed 2018-03-13 | -$11.38M derived: sum of 3 quarters · filed 2018-03-13 | $13.03M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-12-31 | -$4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$7.21M derived: sum of 2 quarters · filed 2018-03-13 | $17.20M derived: sum of 3 quarters · filed 2018-03-13 | $7.48M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $22.13M derived: sum of 2 quarters · filed 2017-11-07 | $12.40M 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $24.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $14.69M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | -$9.72M 10-Q · filed 2017-05-10 | |||
| 2015-12-31 | -$9.03M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |